{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:14:51Z","timestamp":1790396091879,"version":"4.1.0"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2016,11,25]],"date-time":"2016-11-25T00:00:00Z","timestamp":1480032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1,6]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Various complement-mediated renal disorders are treated currently with the complement inhibitor eculizumab. By blocking the cleavage of C5, this monoclonal antibody prevents cell damage caused by complement-mediated inflammation. We included 23 patients with atypical haemolytic uraemic syndrome (aHUS, n\u2009=\u200912), C3 glomerulopathies (C3G, n\u2009=\u20099) and acute antibody-mediated renal graft rejection (AMR, n\u2009=\u20092), treated with eculizumab in 12 hospitals in Germany. We explored the course of complement activation biomarkers and the benefit of therapeutic drug monitoring of eculizumab. Complement activation was assessed by analysing the haemolytic complement function of the classical (CH50) and the alternative pathway (APH50), C3 and the activation products C3d, C5a and sC5b-9 prior to, 3 and 6 months after eculizumab treatment. Eculizumab concentrations were determined by a newly established specific enzyme-linked immunosorbent assay (ELISA). Serum eculizumab concentrations up to 1082 \u03bcg\/ml point to drug accumulation, especially in paediatric patients. Loss of the therapeutic antibody via urine with concentrations up to 56 \u03bcg\/ml correlated with proteinuria. In aHUS patients, effective complement inhibition was demonstrated by significant reductions of CH50, APH50, C3d and sC5b-9 levels, whereas C5a levels were only reduced significantly after 6 months' treatment. C3G patients presented increased C3d and consistently low C3 levels, reflecting ongoing complement activation and consumption at the C3 level, despite eculizumab treatment. A comprehensive complement analysis together with drug monitoring is required to distinguish mode of complement activation and efficacy of eculizumab treatment in distinct renal disorders. Accumulation of the anti-C5 antibody points to the need for a patient-orientated tailored therapy.<\/jats:p>","DOI":"10.1111\/cei.12890","type":"journal-article","created":{"date-parts":[[2016,11,17]],"date-time":"2016-11-17T11:31:33Z","timestamp":1479382293000},"page":"304-315","source":"Crossref","is-referenced-by-count":108,"title":["Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders"],"prefix":"10.1093","volume":"187","author":[{"given":"C","family":"Wehling","sequence":"first","affiliation":[{"name":"Institute of Immunology, University of Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Amon","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, University Hospital T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Bommer","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, ALB FILS Hospital G\u00f6ppingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Hoppe","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, University Hospital Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Kentouche","sequence":"additional","affiliation":[{"name":"Department of Pediatric Immunology, University Hospital Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Schalk","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, University Children's Hospital Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Weimer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Wiesener","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, University Hospital Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Hohenstein","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine III, University Hospital Carl Gustav Carus, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"T\u00f6nshoff","sequence":"additional","affiliation":[{"name":"Department of Pediatrics I, University Children's Hospital Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"B\u00fcscher","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, University Hospital Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Fehrenbach","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Hospital Memmingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6-N","family":"G\u00f6k","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, University Hospital Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Kirschfink","sequence":"additional","affiliation":[{"name":"Institute of Immunology, University of Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,11,25]]},"reference":[{"key":"2021120808030482500_cei12890-bib-0001","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1053\/j.ajkd.2015.03.040","article-title":"Glomerular diseases dependent on complement activation, including atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis, and C3 glomerulopathy: core curriculum 2015","volume":"66","author":"Noris","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2021120808030482500_cei12890-bib-0002","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.molimm.2015.03.012","article-title":"The role of complement in C3 glomerulopathy","volume":"67","author":"Zipfel","year":"2015","journal-title":"Mol Immunol"},{"key":"2021120808030482500_cei12890-bib-0003","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/MOP.0b013e32835df4a3","article-title":"Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases","volume":"25","author":"Nester","year":"2013","journal-title":"Curr Opin Pediatr"},{"key":"2021120808030482500_cei12890-bib-0004","doi-asserted-by":"crossref","first-page":"169","DOI":"10.5527\/wjn.v4.i2.169","article-title":"Complement involvement in kidney diseases: from physiopathology to therapeutical targeting","volume":"4","author":"Salvadori","year":"2015","journal-title":"World J Nephrol"},{"key":"2021120808030482500_cei12890-bib-0005","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneph.2012.214","article-title":"Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies","volume":"8","author":"Zuber","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"2021120808030482500_cei12890-bib-0006","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.molimm.2013.05.224","article-title":"Complement therapy in atypical haemolytic uraemic syndrome (aHUS)","volume":"56","author":"Wong","year":"2013","journal-title":"Mol Immunol"},{"key":"2021120808030482500_cei12890-bib-0007","doi-asserted-by":"crossref","first-page":"E216","DOI":"10.1111\/ctr.12102","article-title":"The use of eculizumab in renal transplantation","volume":"27","author":"Barnett","year":"2013","journal-title":"Clin Transplant"},{"key":"2021120808030482500_cei12890-bib-0008","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.clim.2013.02.014","article-title":"Targeting the complement system in systemic lupus erythematosus and other diseases","volume":"148","author":"Barilla-Labarca","year":"2013","journal-title":"Clin Immunol"},{"key":"2021120808030482500_cei12890-bib-0009","first-page":"2286","article-title":"Eculizumab as rescue therapy in severe resistant lupus nephritis","volume":"54","author":"Pickering","year":"2015","journal-title":"Rheumatology"},{"key":"2021120808030482500_cei12890-bib-0010","doi-asserted-by":"crossref","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","article-title":"Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival","volume":"117","author":"Kelly","year":"2011","journal-title":"Blood"},{"key":"2021120808030482500_cei12890-bib-0011","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/ajh.24278","article-title":"Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study","volume":"91","author":"Loschi","year":"2016","journal-title":"Am J Hematol"},{"key":"2021120808030482500_cei12890-bib-0012","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3324\/haematol.2013.090001","article-title":"Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria","volume":"99","author":"Rondelli","year":"2014","journal-title":"Haematologica"},{"key":"2021120808030482500_cei12890-bib-0013","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"N Engl J Med"},{"key":"2021120808030482500_cei12890-bib-0014","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/ejh.12021","article-title":"Predictors of hemoglobin response to eculizumab therapy in paroxysmal nocturnal hemoglobinuria","volume":"90","author":"DeZern","year":"2013","journal-title":"Eur J Haematol"},{"key":"2021120808030482500_cei12890-bib-0015","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1681\/ASN.2011121186","article-title":"Pathology after eculizumab in dense deposit disease and C3 GN","volume":"23","author":"Herlitz","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2021120808030482500_cei12890-bib-0016","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.transproceed.2013.02.062","article-title":"Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: case reports","volume":"45","author":"Kocak","year":"2013","journal-title":"Transplant Proc"},{"key":"2021120808030482500_cei12890-bib-0017","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00277-012-1622-z","article-title":"Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation","volume":"92","author":"Carr","year":"2013","journal-title":"Ann Hematol"},{"key":"2021120808030482500_cei12890-bib-0018","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1053\/j.ajkd.2014.01.434","article-title":"Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases","volume":"64","author":"Ardissino","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2021120808030482500_cei12890-bib-0019","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.2215\/CJN.10181110","article-title":"Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome","volume":"6","author":"Nester","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021120808030482500_cei12890-bib-0020","first-page":"133","article-title":"Complement and complement fixation","volume-title":"Experimental immunochemistry","author":"Mayer","year":"1961"},{"key":"2021120808030482500_cei12890-bib-0021","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/ajcp\/79.1.65","article-title":"A study of optimal reaction conditions for an assay of the human alternative complement pathway","volume":"79","author":"Joiner","year":"1983","journal-title":"Am J Clin Pathol"},{"key":"2021120808030482500_cei12890-bib-0022","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0022-1759(81)90107-1","article-title":"Double-decker rocket immunoelectrophoresis for direct quantitation of complement C3 split products with C3d specificities in plasma","volume":"44","author":"Brandslund","year":"1981","journal-title":"J Immunol Methods"},{"key":"2021120808030482500_cei12890-bib-0023","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0022-1759(82)90386-6","article-title":"A new screening test for C3 nephritis factor based on a stable cell bound convertase on sheep erythrocytes","volume":"51","author":"Rother","year":"1982","journal-title":"J Immunol Methods"},{"key":"2021120808030482500_cei12890-bib-0024","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-3083.1985.tb01871.x","article-title":"Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex","volume":"22","author":"Mollnes","year":"1985","journal-title":"Scand J Immunol"},{"key":"2021120808030482500_cei12890-bib-0025","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1046\/j.1365-2249.2002.01772.x","article-title":"Complement activation in infective endocarditis: correlation with extracardiac manifestations and prognosis","volume":"127","author":"Messias-Reason","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"2021120808030482500_cei12890-bib-0026","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/jth.12615","article-title":"Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome","volume":"12","author":"Cugno","year":"2014","journal-title":"J Thromb Haemost"},{"key":"2021120808030482500_cei12890-bib-0027","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1053\/j.ajkd.2015.11.009","article-title":"Discontinuation of eculizumab in a patient with atypical hemolytic uremic syndrome due to a mutation in CFH","volume":"67","author":"Habbig","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2021120808030482500_cei12890-bib-0028","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/cei.12426","article-title":"Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission","volume":"181","author":"Volokhina","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"2021120808030482500_cei12890-bib-0029","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"key":"2021120808030482500_cei12890-bib-0030","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00467-015-3078-6","article-title":"A complicated case of atypical hemolytic uremic syndrome with frequent relapses under eculizumab","volume":"30","author":"Schalk","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"2021120808030482500_cei12890-bib-0031","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2215\/CJN.12901211","article-title":"Eculizumab for dense deposit disease and C3 glomerulonephritis","volume":"7","author":"Bomback","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021120808030482500_cei12890-bib-0032","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000368592","article-title":"Eculizumab in the treatment of membranoproliferative glomerulonephritis","volume":"128","author":"Bomback","year":"2014","journal-title":"Nephron Clin Pract"},{"key":"2021120808030482500_cei12890-bib-0033","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1007\/s00467-013-2503-y","article-title":"Eculizumab and recurrent C3 glomerulonephritis","volume":"28","author":"Gurkan","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"2021120808030482500_cei12890-bib-0034","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.clim.2015.08.009","article-title":"Applying complement therapeutics to rare diseases","volume":"161","author":"Reis","year":"2015","journal-title":"Clin Immunol"},{"key":"2021120808030482500_cei12890-bib-0035","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1182\/blood-2014-07-589366","article-title":"Eculizumab fails to inhibit generation of C5a in vivo","volume":"124","author":"Burwick","year":"2014","journal-title":"Blood"},{"key":"2021120808030482500_cei12890-bib-0036","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1182\/blood-2015-06-642553","article-title":"Response: maternal and cord C5a in response to eculizumab","volume":"126","author":"Burwick","year":"2015","journal-title":"Blood"},{"key":"2021120808030482500_cei12890-bib-0037","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1182\/blood-2015-03-637645","article-title":"Eculizumab treatment efficiently prevents C5 cleavage without C5a generation in vivo","volume":"126","author":"Volokhina","year":"2015","journal-title":"Blood"},{"key":"2021120808030482500_cei12890-bib-0038","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.4049\/jimmunol.0903678","article-title":"Molecular intercommunication between the complement and coagulation systems","volume":"185","author":"Amara","year":"2010","journal-title":"J Immunol"},{"key":"2021120808030482500_cei12890-bib-0039","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1182\/blood-2012-02-412080","article-title":"Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway","volume":"120","author":"Krisinger","year":"2012","journal-title":"Blood"},{"key":"2021120808030482500_cei12890-bib-0040","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood-2014-09-600411","article-title":"Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS","volume":"125","author":"Cofiell","year":"2015","journal-title":"Blood"},{"key":"2021120808030482500_cei12890-bib-0041","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nm1419","article-title":"Generation of C5a in the absence of C3: a new complement activation pathway","volume":"12","author":"Huber-Lang","year":"2006","journal-title":"Nat Med"},{"key":"2021120808030482500_cei12890-bib-0042","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1182\/blood-2011-06-359646","article-title":"Design and development of TT30, a novel C3d-targeted C3\/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases","volume":"118","author":"Fridkis-Hareli","year":"2011","journal-title":"Blood"},{"key":"2021120808030482500_cei12890-bib-0043","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jim.2016.05.009","article-title":"Novel biomarker and easy to perform ELISA for monitoring complement inhibition in patients with atypical hemolytic uremic syndrome treated with eculizumab","volume":"435","author":"Riedl","year":"2016","journal-title":"J Immunol Methods"},{"key":"2021120808030482500_cei12890-bib-0044","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/tri.12396","article-title":"Antibody-mediated rejection despite inhibition of terminal complement","volume":"27","author":"Bentall","year":"2014","journal-title":"Transpl Int"},{"key":"2021120808030482500_cei12890-bib-0045","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1111\/jth.12639","article-title":"Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis","volume":"12","author":"Wehling","year":"2014","journal-title":"J Thromb Haemost"},{"key":"2021120808030482500_cei12890-bib-0046","doi-asserted-by":"crossref","first-page":"e1506","DOI":"10.1542\/peds.2014-3503","article-title":"Case report: benefits and challenges of long-term eculizumab in atypical hemolytic uremic syndrome","volume":"135","author":"Cullinan","year":"2015","journal-title":"Pediatrics"},{"key":"2021120808030482500_cei12890-bib-0047","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/19420862.2015.1086049","article-title":"Therapeutic drug monitoring of eculizumab: rationale for an individualized dosing schedule","volume":"7","author":"Gatault","year":"2015","journal-title":"MAbs"},{"key":"2021120808030482500_cei12890-bib-0048","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ejim.2013.05.008","article-title":"Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy","volume":"24","author":"Fakhouri","year":"2013","journal-title":"Eur J Intern Med"},{"key":"2021120808030482500_cei12890-bib-0049","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","author":"Loirat","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"2021120808030482500_cei12890-bib-0050","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00467-014-2990-5","article-title":"Eculizumab hepatotoxicity in pediatric aHUS","volume":"30","author":"Hayes","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"2021120808030482500_cei12890-bib-0051","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.clim.2015.05.018","article-title":"Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome","volume":"160","author":"Volokhina","year":"2015","journal-title":"Clin Immunol"},{"key":"2021120808030482500_cei12890-bib-0052","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s00431-012-1763-z","article-title":"A time for reappraisal of \u2018atypical\u2019 hemolytic uremic syndrome: should all patients be treated the same?","volume":"171","author":"Ruebner","year":"2012","journal-title":"Eur J Pediatr"},{"key":"2021120808030482500_cei12890-bib-0053","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1016\/j.transproceed.2012.07.141","article-title":"Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report","volume":"44","author":"Xie","year":"2012","journal-title":"Transplant Proc"},{"key":"2021120808030482500_cei12890-bib-0054","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2014-03-560540","article-title":"Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab","volume":"125","author":"Peffault de Latour","year":"2015","journal-title":"Blood"},{"key":"2021120808030482500_cei12890-bib-0055","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/qjmed\/hcv082","article-title":"A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience","volume":"109","author":"Sheerin","year":"2016","journal-title":"QJM"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcei.12890","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cei.12890","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cei.12890","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/187\/2\/304\/41643095\/cei12890.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/187\/2\/304\/41643095\/cei12890.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T16:27:33Z","timestamp":1641054453000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/187\/2\/304\/6412020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,25]]},"references-count":55,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,11,25]]},"published-print":{"date-parts":[[2017,1,6]]}},"URL":"https:\/\/doi.org\/10.1111\/cei.12890","relation":{},"ISSN":["1365-2249","0009-9104"],"issn-type":[{"value":"1365-2249","type":"electronic"},{"value":"0009-9104","type":"print"}],"subject":[],"published-other":{"date-parts":[[2017,2]]},"published":{"date-parts":[[2016,11,25]]}}}